Company / Operating Cash Flow
Atea Pharmaceuticals, Inc. Operating Cash Flow History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$121.0M
FY2022
5-year range
-$121.0M / -$7.9M
FY2020-FY2022
Trend
-843.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed -843% YoY in FY2022, a notable deviation from the 2-year average annual change of -453%.
Based on SEC 10-K filings.
-$121M in FY2022.
Declined from -$8M to -$121M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating cash flow decreased 843.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 10.30 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$121.0M | -843.0% |
| FY2021 | -$12.8M | -62.2% |
| FY2020 | -$7.9M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026